Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.

about

Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.

P2860

Q55247585-7AC8C8A4-2ACC-48B3-B875-3E0A9A6A720E

P2860

Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.

Item

http://www.wikidata.org/entity/Q47138288

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Potential synergistic effect o ...... h chemotherapy in lung cancer.

@en

Potential synergistic effect o ...... h chemotherapy in lung cancer.

@nl

type

Item

label

Potential synergistic effect o ...... h chemotherapy in lung cancer.

@en

Potential synergistic effect o ...... h chemotherapy in lung cancer.

@nl

prefLabel

Potential synergistic effect o ...... h chemotherapy in lung cancer.

@en

Potential synergistic effect o ...... h chemotherapy in lung cancer.

@nl

P1476

Potential synergistic effect o ...... h chemotherapy in lung cancer.

@en

P2093

Efrosini Kioseoglou

http://www.w3.org/2001/XMLSchema#string

Kalliopi Domvri

http://www.w3.org/2001/XMLSchema#string

Konstantinos Porpodis

http://www.w3.org/2001/XMLSchema#string

Konstantinos Zarogoulidis

http://www.w3.org/2001/XMLSchema#string

Nikolaos Zogas

http://www.w3.org/2001/XMLSchema#string

Paul Zarogoulidis

http://www.w3.org/2001/XMLSchema#string

Savvas Petanidis

http://www.w3.org/2001/XMLSchema#string

Wolfgang Hohenforst-Schmidt

http://www.w3.org/2001/XMLSchema#string

P2860

A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool

A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.

PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

Characterization of the A2B adenosine receptor from mouse, rabbit, and dog.

Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G

Cyclic GMP phosphodiesterase-5: target of sildenafil.

PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells.

P304

3648-3656

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.21783

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29151951

http://www.w3.org/2001/XMLSchema#string

P932

5688917

http://www.w3.org/2001/XMLSchema#string

Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.

about

P2860

P2860

Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932